title: Predictors of remission in juvenile-onset recurrent respiratory papillomatosis.
abstract: OBJECTIVE
  To determine factors associated with remission of juvenile-onset recurrent respiratory papillomatosis (JORRP).
  
  
  METHODS
  Longitudinal study.
  
  
  METHODS
  Twenty-two tertiary care centers located across the United States.
  
  
  METHODS
  The study included 165 patients diagnosed as having JORRP between January 1, 1997, and December 31, 2000. Kaplan-Meier curves and Cox proportional hazards models were used to determine associations between predictors and remission.
  
  
  METHODS
  Surgical excision and drug therapy.
  
  
  METHODS
  Remission of JORRP, defined as no surgical procedures for at least 1 year, as associated with age at diagnosis, drug therapy in the first year after diagnosis, number of surgical procedures in the first year after diagnosis, and number of anatomical sites of disease at diagnosis. Demographic factors (sex and race) and Medicaid status were also evaluated.
  
  
  RESULTS
  Older age at diagnosis was positively associated with remission of JORRP (hazards ratio for every increase of 1 year in age, 1.13; 95% confidence interval, 1.03-1.23).
  
  
  CONCLUSIONS
  Younger children were found to have persistent disease and often underwent an increased number of surgical procedures in the first year after diagnosis of JORRP. Sex and race were not important factors in determining remission.
authors.affiliation: Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.
authors.forename: Snehal
authors.initials: S
authors.lastname: Ruparelia
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Unger
authors.forename: Rosane
authors.initials: R
authors.lastname: Nisenbaum
authors.forename: Craig S
authors.initials: CS
authors.lastname: Derkay
authors.forename: William C
authors.initials: WC
authors.lastname: Reeves
mesh_terms: D017677:Age Distribution; D000367:Age Factors; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D008484:Medicaid; D015999:Multivariate Analysis; D010212:Papilloma / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012008:Recurrence; D012042:Registries; D012074:Remission Induction / Q000379:methods; D012086:Reoperation / Q000706:statistics & numerical data; D012142:Respiratory Tract Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology